Logica.ai: Accelerating Small Molecule Drug Discovery with AI and Wet Lab Integration

Logica.ai is a cutting-edge AI-driven drug discovery and development platform developed through a strategic collaboration between Charles River and Valo Health. Designed to transform the pharmaceutical pipeline, it seamlessly integrates artificial intelligence and machine learning with real-world wet lab experimentation to accelerate the journey from target identification to preclinical development. By combining vast virtual and physical compound libraries with high-precision predictive modeling, Logica.ai enables rapid screening of billions of molecules per cycle and delivers highly viable drug candidates with a claimed 90% success rate in generating advanceable lead series. Its risk-sharing business model offers predictable costs tied to key milestones, making it a reliable partner for pharmaceutical innovation. Ideal for research-driven organizations, Logica.ai supports clients at any stage of drug discovery—whether they have a validated target, a target needing validation, or an ongoing lead program.

Key Features:

• AI-Driven Molecular Design: Leverages machine learning to generate novel, high-quality small molecule candidates.
• Closed-Loop Integration: Combines predictive modeling with real-time biological assay data for continuous optimization.
• Massive Compound Libraries: Access to over 30 billion virtual compounds, 1 million HTS data points, and 13 billion DEL data points.
• Logica-AL® (Advanceable Lead): Delivers a robust lead series with multiple compounds meeting design criteria, ready for advancement.
• Logica-C® (Candidate): Produces optimized drug candidates suitable for GLP toxicology, IND-enabling studies, or clinical development.
• Risk-Sharing Business Model: Fixed budget tied to value-inflection points, reducing financial uncertainty.
• Therapeutic Area Expertise: Covers CNS, Oncology, Fibrosis, Respiratory, Anti-infective, and other complex disease areas.
• Target Class Diversity: Supports Kinases, Phenotypic targets, Ion channels, Proteases, Enzymes, RNA targets, Transcription factors, Membrane receptors, GPCRs, and more.
• End-to-End Acceleration: Reduces timelines by at least one year, improving predictability and success rates.
• Flexible Engagement: Clients can participate in either Logica-AL or Logica-C stages independently, without obligation to proceed.
• Comprehensive Resources: Offers white papers, blogs, webinars, videos, podcasts, brochures, and publication articles for deep insights.
• Global Collaboration & Events: Hosts industry events like LSX World Congress USA and Discovery on Target, fostering innovation and networking.

Pricing: Logica.ai operates under a risk-sharing model with predictable costs, offering a flexible and transparent pricing structure tailored to project milestones. While specific pricing details are not publicly listed, the model is designed to minimize financial risk and maximize return on investment.

Conclusion: Logica.ai stands at the forefront of AI-powered pharmaceutical innovation, merging decades of wet lab expertise with advanced machine learning to deliver faster, more reliable, and higher-quality drug discovery outcomes. Its transformative approach, proven track record across 50+ projects, and patient-centered vision make it an invaluable partner for enterprises and research teams aiming to revolutionize small molecule development.